Logo Image
News
Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Watch
Expert ConversationsShows & PodcastsNews & Analysis
Conferences
Publications
All JournalsEditorial BoardFor AuthorsYear in Review
More
Events
Frontline ForumSatellite Sessions
CME/CE
Resources
Awareness MonthThe Bispecifics NetworkNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career Center

Subscribe

  • News
  • Watch
  • Conferences
  • Publications
  • Events
  • CME/CE
  • Resources
  • Career Center
  • Subscribe
  • Adverse Effects
  • Artificial Intelligence
  • Brain Cancer
  • Breast Cancer
    • HER2-Positive Breast Cancer
    • Triple-Negative Breast Cancer
  • Gastrointestinal Cancer
    • Colorectal Cancer
    • Esophageal Cancer
    • Pancreatic Cancer
    • Gastric Cancer
    • Liver Cancer
  • Genitourinary Cancers
    • Kidney Cancer
    • Bladder Cancer
    • Prostate Cancer
  • Gynecologic Cancers
    • Endometrial Cancer
    • Ovarian Cancer
    • Cervical Cancer
  • Head & Neck Cancer
  • Hematologic Oncology
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Myeloproliferative Neoplasms
  • Infection
    • Vaccines
  • Leukemia
  • Lung Cancer
    • Small Cell Lung Cancer (SCLC)
    • Non-Small Cell Lung Cancer (NSCLC)
  • Lymphoma
  • Neuroendocrine Tumors
  • Oncology
  • Pediatric Cancers
  • Psycho-Oncology
  • Radiation Oncology
  • Sarcoma
  • Screening
  • Skin Cancer & Melanoma
  • Surgery
  • Thyroid Cancer
Spotlight -
Psycho-Oncology|
Artificial Intelligence|
Career Center|
Radiation Oncology|
Surgery
Advertisement

Alvaro Rodriguez-lescure, MD

Advertisement

Articles by Alvaro Rodriguez-lescure, MD

UFT/Methotrexate/Leucovorin for Breast Cancer Patients in Progression After HDCT/PBPC Support

ByMiguel Martin, MD, PhD,Antonio Casado, MD,José Antonio López-Martin, MD,Alvaro Rodriguez-lescure, MD,Yago Nieto, MD,Francisco Ayala, MD,Eduardo Diaz-rubio, MD, PhD
September 2nd 1997

Twenty-four patients with metastatic breast cancer that had progressed after high-dose chemotherapy with peripheral blood progenitor cell (PBPC) support were given intramuscular methotrexate in combination with oral

Advertisement

Latest Updated Articles

  • UFT/Methotrexate/Leucovorin for Breast Cancer Patients  in Progression After HDCT/PBPC Support
    UFT/​Methotrexate/​Leucovorin for Breast Cancer Patients in Progression After HDCT/​PBPC Support

    September 2nd 1997



Advertisement
Advertisement

Trending on CancerNetwork

1

Closing the HCC Surveillance Gap in MASLD Without Cirrhosis

2

Rethinking Surveillance and Multidisciplinary Care in MASLD-Related HCC

3

Weighing HCC Surveillance for Patients With MASLD and F3 Fibrosis

4

Closing the Gap Between Tumor Board Recommendations and Liver Cancer Care

5

Building Systems to Catch Liver and Other Cancers in Patients With MASLD

  • About
  • Advertise
  • CureToday.com
  • OncLive.com
  • OncNursingNews.com
  • TargetedOnc.com
  • Editorial
  • Contact
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Personal Information
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

Brand Logo

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us